AstraZeneca is paying $200 million upfront to license TQC3721, an experimental COPD drug from Sino Biopharmaceutical's subsidiary, for all markets outside China. The deal could be worth up to $1.9 billion in total milestones. Phase II trial data from China showed the drug significantly improved lung function compared to placebo, offering potential new hope for patients who don't respond well to existing therapies.
AstraZeneca is doubling down on COPD with a major new licensing deal. The pharma giant has agreed to pay $200 million upfront to Chia Tai Tianqing Pharmaceutical Group — a subsidiary of Hong Kong-listed Sino Biopharmaceutical — for the rights to develop, manufacture, and commercialize TQC3721 everywhere outside of China. The total deal could reach up to $1.9 billion, including development, regulatory, and sales milestones.
TQC3721 caught AstraZeneca's eye after a Phase II trial in China showed it "significantly improved lung function and symptoms" compared to placebo — a meaningful result in a disease space where many patients still suffer flare-ups despite current treatments. AstraZeneca already has its own experimental COPD therapy, tozorakimab, which showed a meaningful reduction in moderate-to-severe flare-ups in a late-stage trial earlier this year.
By the Numbers:
Why it matters: COPD is the world's third-leading cause of death, yet treatment options remain limited for many patients. This deal signals growing pharmaceutical investment in next-generation respiratory therapies — and could eventually bring a novel treatment option to millions of patients worldwide.
